AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31134220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic navigation system (surgery performed with navigation system)
Number of subjects: 10
Study 31134220 — intervention group
Group type: COMPARATOR
Intervention: Flapless surgery
Number of subjects: 10
Study 31134220 — intervention group
Group type: COMPARATOR
Intervention: Open-flap surgery
Number of subjects: 10
Study 31134220 — intervention group
Group type: COMPARATOR
Intervention: Piezoelectric tips
Number of subjects: 10
Study 31134220 — intervention group
Group type: COMPARATOR
Intervention: Conventional burs
Number of subjects: 10
Study 28117614 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus vinorelbine (VC)
Number of subjects: 52
Study 28117614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GC)
Number of subjects: 52
Study 28117614 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 25909320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention with additional medication reminders and adherence assessment via text message
Number of subjects: 76
Study 25909320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention
Number of subjects: 76
Study 25909320 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard treatment with naltrexone)
Number of subjects: 76
Study 25909320 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76
Study 25909320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 76
Study 23447696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment
Number of subjects: 107
Study 23447696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment with TMP-SMX prophylaxis
Number of subjects: 107
Study 23447696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) treatment without TMP-SMX prophylaxis
Number of subjects: 107
Study 23447696 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study 21269351 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous collagen induction (PCI) - four sessions (4 weeks apart)
Number of subjects: 30
Study 21269351 — intervention group
Group type: COMPARATOR
Intervention: 100% TCA CROSS - four sessions (4 weeks apart)
Number of subjects: 30
Study 18216764 — intervention group
Group type: EXPERIMENTAL
Intervention: Remi-1 group (1 ng x mL(‐1) remifentanil)
Number of subjects: 80
Study 18216764 — intervention group
Group type: EXPERIMENTAL
Intervention: Remi-2 group (2 ng x mL(‐1) remifentanil)
Number of subjects: 80
Study 18216764 — intervention group
Group type: EXPERIMENTAL
Intervention: Remi-3 group (3 ng x mL(‐1) remifentanil)
Number of subjects: 80
Study 18216764 — intervention group
Group type: EXPERIMENTAL
Intervention: Remi-4 group (4 ng x mL(‐1) remifentanil)
Number of subjects: 80
Study 18216764 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 80
Study 16521223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) maintained at 2‐4 mmHg during hepatectomy
Number of subjects: 50
Study 16521223 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine hepatectomy without lowering CVP)
Number of subjects: 50
Study 12878286 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 0
Study 12878286 — intervention group
Group type: COMPARATOR
Intervention: Latex condom (Control)
Number of subjects: 0
Study 11101061 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 1 microg/kg daily
Number of subjects: 39
Study 11101061 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 4 microg/kg daily
Number of subjects: 39
Study 11101061 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 8 microg/kg three times per week
Number of subjects: 39
Study 11101061 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 39
Study 11101061 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times per week
Number of subjects: 39
Study 8820468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate 50, 100, 150, 200, 250, 300, or 400 mg
Number of subjects: 120
Study 8820468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8820468 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate (doses up to 400 mg)
Number of subjects: 120
Study 1420514 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls
Number of subjects: 224
Study 1420514 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical assessments
Number of subjects: 224
Study 1420514 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire
Number of subjects: 224
Study 1420514 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma beta-carotene levels
Number of subjects: 224
Study 3975255 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin granules
Number of subjects: 56
Study 3975255 — intervention group
Group type: COMPARATOR
Intervention: Buffered aspirin tablets
Number of subjects: 56
Study 3975255 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 56
Study 29373334 — intervention group
Group type: EXPERIMENTAL
Intervention: DIVA system (automated vasopressor administration)
Number of subjects: 236
Study 29373334 — intervention group
Group type: COMPARATOR
Intervention: Manual vasopressor bolus administration
Number of subjects: 236
Study 27134127 — intervention group
Group type: EXPERIMENTAL
Intervention: Subxiphoid single‐incision VATS
Number of subjects: 43
Study 27134127 — intervention group
Group type: COMPARATOR
Intervention: Intercostal uniport VATS
Number of subjects: 43
Study 24611925 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week telephone-based motivational interviewing (MI) intervention to improve physical activity (n = 44)
Number of subjects: 92
Study 24611925 — intervention group
Group type: COMPARATOR
Intervention: 12-week wait-list control group (n = 48)
Number of subjects: 92
Study 24611925 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week telephone-based motivational interviewing (MI) intervention
Number of subjects: 92
Study 22592048 — intervention group
Group type: COMPARATOR
Intervention: 50.4 Gy in 28 fractions (arm A)
Number of subjects: 248
Study 22592048 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.4 Gy in 28 fractions + endorectal boost (10 Gy in 2 fractions) (arm B)
Number of subjects: 248
Study 20055898 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent research programme on drugs funded by the Italian Medicines Agency (AIFA)
Number of subjects: 0
Study 18374405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunotherapy with alum-adsorbed grass pollen vaccine (Alutard SQ)
Number of subjects: 18
Study 18374405 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 18
Study 15878068 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 400
Study 15878068 — intervention group
Group type: COMPARATOR
Intervention: Small-incision
Number of subjects: 400
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 100 mg/qd
Number of subjects: 140
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 200 mg/qd
Number of subjects: 140
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 200 mg/bid
Number of subjects: 140
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 400 mg/qd
Number of subjects: 140
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 800 mg on Day 1 followed by 400 mg on Days 2-5
Number of subjects: 140
Study 12645994 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-270201 (BCX-1812) 800 mg on Days 1-5
Number of subjects: 140
Study 12645994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 9796233 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded response in Task1
Number of subjects: 0
Study 9796233 — intervention group
Group type: COMPARATOR
Intervention: Unspeeded delayed response in Task1
Number of subjects: 0
Study 9796233 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster responses in Task1
Number of subjects: 0
Study 7641477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate flexion and extension splinting
Number of subjects: 68
Study 7641477 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion
Number of subjects: 68
Study 7641477 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritic knees
Number of subjects: 68
Study 7641477 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid knees
Number of subjects: 68
Study 2515342 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐schistosomal drugs plus prednisolone (Group II)
Number of subjects: 26
Study 2515342 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐schistosomal drugs plus cyclosporine (Group III)
Number of subjects: 26
Study 2515342 — intervention group
Group type: COMPARATOR
Intervention: Anti‐schistosomal drugs (Group I)
Number of subjects: 26
Study 345749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction of neuroleptic drugs (mean 75 mg equivalent of chlorpromazine)
Number of subjects: 48
Study 345749 — intervention group
Group type: COMPARATOR
Intervention: Maintained on matched dosages of neuroleptics (mean 150 mg equivalent of chlorpromazine)
Number of subjects: 48
Study 345749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction of neuroleptic drugs (mean 8 mg equivalent of chlorpromazine)
Number of subjects: 48
Study 31118095 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE-MUSIC/SPANISH
Number of subjects: 144
Study 31118095 — intervention group
Group type: COMPARATOR
Intervention: ENGAGE-DISCOVERY
Number of subjects: 144
Study 29622047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group
Number of subjects: 0
Study 29622047 — intervention group
Group type: COMPARATOR
Intervention: Sham meditation group
Number of subjects: 0
Study 27743547 — intervention group
Group type: EXPERIMENTAL
Intervention: TIME intervention (N=22)
Number of subjects: 44
Study 27743547 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, N=22)
Number of subjects: 44
Study 25470078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation (VES)
Number of subjects: 42
Study 25470078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23582830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (n=66)
Number of subjects: 129
Study 23582830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=63)
Number of subjects: 129
Study 20177118 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 30 microg once weekly plus placebo (n = 12)
Number of subjects: 67
Study 20177118 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 60 microg once weekly plus placebo (n = 11)
Number of subjects: 67
Study 20177118 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 30 microg twice weekly (n = 11)
Number of subjects: 67
Study 20177118 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFNbeta‐1a 60 microg twice weekly (n = 11)
Number of subjects: 67
Study 20177118 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice weekly (n = 22)
Number of subjects: 67
Study 18950449 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB with 10 administrations of 10 mg levobupivacaine every other day for 10 treatments, followed by one administration per month for 6 months
Number of subjects: 50
Study 18950449 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg/day and gabapentin 1800 mg/day orally for 6 months, followed by SGB therapy in the 7th month
Number of subjects: 50
Study 16669726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 98
Study 16669726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Dextroamphetamine + Psychotherapy)
Number of subjects: 98
Study 16669726 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 98
Study 16669726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 16669726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Paroxetine + Psychotherapy)
Number of subjects: 98
Study 16669726 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication + Psychological therapy
Number of subjects: 98
Study 12904810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg tablet
Number of subjects: 60
Study 12904810 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 60
Study 10720591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg bolus injection followed by 50 mg/h continuous infusion for 3 hours)
Number of subjects: 8
Study 10720591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10720591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 8
Study 9594180 — intervention group
Group type: EXPERIMENTAL
Intervention: THAM (4 to 5 ml/kg infused intravenously 2 to 3 times daily)
Number of subjects: 50
Study 9594180 — intervention group
Group type: COMPARATOR
Intervention: Control (no THAM treatment)
Number of subjects: 50
Study 1549435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for tap water
Number of subjects: 0
Study 1549435 — intervention group
Group type: COMPARATOR
Intervention: Oddity detection task
Number of subjects: 0
Study 3907641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-benzo-alpha-pyrone/troxerutin combination (Venalot Depot)
Number of subjects: 41
Study 3907641 — intervention group
Group type: EXPERIMENTAL
Intervention: benzarone
Number of subjects: 41
Study 30709746 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 95
Study 30709746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 29735457 — intervention group
Group type: EXPERIMENTAL
Intervention: Phellodendron wet compress
Number of subjects: 600
Study 29735457 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate solution wet compress
Number of subjects: 600
Study 26881793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led case management intervention
Number of subjects: 12181
Study 26881793 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12181
Study 26109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (SC)
Number of subjects: 619
Study 26109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT)
Number of subjects: 619
Study 26109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival post-ASCT
Number of subjects: 619
Study 26109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS)
Number of subjects: 619
Study 26109202 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ASCT EFS
Number of subjects: 619
Study 23121272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen combination
Number of subjects: 0
Study 23121272 — intervention group
Group type: COMPARATOR
Intervention: Butalbital formulation
Number of subjects: 0
Study 19502017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 202
Study 19502017 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 202
Study 18284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 3320
Study 18284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 3320
Study 18284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy for hypertension
Number of subjects: 3320
Study 18284462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 3320
Study 15918446 — intervention group
Group type: EXPERIMENTAL
Intervention: Xcoating coated condensed extra-corporeal circuit (CondECC)
Number of subjects: 22
Study 15918446 — intervention group
Group type: COMPARATOR
Intervention: Fully heparin-coated CPB circuit (control)
Number of subjects: 22
Study 12095495 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral hormonal contraception (Cileste: 250 microg of norgestimat and 35 microg of ethinylestradiol; Marvelon: 150 microg of desogestrel and 30 microg of ethinylestradiol)
Number of subjects: 0
Study 12095495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cileste
Number of subjects: 0
Study 12095495 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 0
Study 10068412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime insulin plus metformin (2 g)
Number of subjects: 96
Study 10068412 — intervention group
Group type: COMPARATOR
Intervention: Bedtime insulin plus glyburide
Number of subjects: 96
Study 10068412 — intervention group
Group type: COMPARATOR
Intervention: Bedtime insulin plus both oral drugs (glyburide and metformin)
Number of subjects: 96
Study 10068412 — intervention group
Group type: COMPARATOR
Intervention: Bedtime and morning insulin
Number of subjects: 96
Study 7985893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceredase (alglucerase) infused every 2 weeks for 9 months at a dose of 60 U/kg body weight
Number of subjects: 30
Study 7985893 — intervention group
Group type: COMPARATOR
Intervention: Cerezyme (imiglucerase) infused every 2 weeks for 9 months at a dose of 60 U/kg body weight
Number of subjects: 30
Study 7985893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceredase
Number of subjects: 30
Study 7985893 — intervention group
Group type: COMPARATOR
Intervention: Cerezyme
Number of subjects: 30
Study 2974416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 27
Study 2974416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30353773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (1-hour sessions weekly for 8 weeks)
Number of subjects: 60
Study 30353773 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (relaxation techniques weekly for 8 weeks)
Number of subjects: 60
Study 30353773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 29631820 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care preappointment information plus estimated appointment wait time
Number of subjects: 50
Study 29631820 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care preappointment information
Number of subjects: 50
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort care
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic care
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical care
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy perception of resident having less than six months to live
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Older resident age
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse resident cognitive impairment
Number of subjects: 402
Study 28797857 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy asked about goals of care preferences by NH health care provider
Number of subjects: 402
Study 26238287 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 699
Study 24216675 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid‐mediated photodynamic therapy (ALA‐PDT) for lesions <0.5 cm
Number of subjects: 361
Study 24216675 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT plus cryotherapy for lesions 0.5‐2.0 cm
Number of subjects: 361
Study 24216675 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT retreatment after cryotherapy or CO2 laser treatment for lesions >2.0‐4.0 cm
Number of subjects: 361
Study 21446870 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon system
Number of subjects: 27
Study 21446870 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventionally ligated edgewise bracket system)
Number of subjects: 27
Study 18317189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation (GI)
Number of subjects: 1378
Study 18317189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation plus training of practice nurses in motivational counseling (MC)
Number of subjects: 1378
Study 18317189 — intervention group
Group type: COMPARATOR
Intervention: Postal dissemination of the guideline (controls)
Number of subjects: 1378
Study 21395626 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502®)
Number of subjects: 50
Study 21395626 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 50
Study 16120070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of analgesics and psychotropics
Number of subjects: 523
Study 16120070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of psychotropics and opioids
Number of subjects: 523
Study 16120070 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of opioids among concomitant users
Number of subjects: 523
Study 16120070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant users of analgesics
Number of subjects: 523
Study 16120070 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant users
Number of subjects: 523
Study 12399278 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 micro g)
Number of subjects: 110
Study 12399278 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (1000 micro g)
Number of subjects: 110
Study 12399278 — intervention group
Group type: COMPARATOR
Intervention: Phylloquinone supplementation (250 micro g)
Number of subjects: 110
Study 12399278 — intervention group
Group type: COMPARATOR
Intervention: Phylloquinone supplementation (375 micro g)
Number of subjects: 110
Study 12399278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110